October 25, 2017
Future Medicinal Chemistry and the International Chemical Biology Society announce their official partnership
The International Chemical Biology Society (ICBS) and the Future Science Group have announced an exciting new collaboration, with the journal Future Medicinal Chemistry becoming an official partner publication of the Society.
Following an announcement at the 6th Official Conference of the ICBS, in Shanghai, China (17–20 October), Future Medicinal Chemistry and the ICBS will work together closely to publish cutting-edge content on chemical biology, and to provide a variety of benefits to members of the ICBS.
The journal will welcome members of the ICBS onto their highly respected Editorial Board, allowing them to work together to ensure the most relevant and interesting content is published in the field of chemical biology, including a number of themed issues each year. New members will join existing Senior Editor Professor Jonathan Baell (Monash University, Australia), a member of the ICBS Board of Directors, who was instrumental in initiating the partnership together with Professor Zaneta Nikolovska-Coleska (University of Michigan, USA) and other members of the ICBS Board of Directors.
ICBS members will receive a variety of benefits from the publisher, including discounted journal subscriptions and reduced fees for the journal’s optional Open Access service. In addition, members of the ICBS will benefit from the unique networking and collaboration opportunities provided by the journal’s partner website MedChemNet.
“In October 2011, Chemical Biologists from more than 20 countries across the globe attended the inaugural Chemical Biology meeting held in Kansas City and culminated in the formation of the International Chemical Biology Society (ICBS). Our Society is providing an important international forum to bring together cross-disciplinary scientists to address urgent challenges in our life across the globe with innovative chemical biology approaches and ideas. We promote an open and inclusive organization for the global community and foster the career development of young scientists and trainees. This non-exclusive, exciting partnership with the highly respected Future Medicinal Chemistry adds a new vehicle for our members to rapidly disseminate their cutting edge discoveries and offers an effective platform for exchange of ideas and training of the next generation of chemical biologists,” stated by the President of the ICBS, Professor Lixin Zhang (East China University of Science and Technology, Shanghai, China).
“Future Medicinal Chemistry is one of our most successful titles, publishing content from an international array of key opinion leaders,” commented Future Science Group Managing Director, Phil Garner. “This partnership will further strengthen the high-quality content we are able to offer our readers, by giving us the opportunity to work with the highly esteemed experts that make up the membership of the International Chemical Biology Society.”
Those interested in joining the ICBS should visit their website here: http://www.chemicalbiology.org/. Future Medicinal Chemistry can be read via its newly-relaunched website here: https://www.future-science.com/journal/fmc.
ABOUT THE INTERNATIONAL CHEMICAL BIOLOGY SOCIETY
The International Chemical Biology Society (ICBS) is an independent, nonprofit organization dedicated to promoting research and educational opportunities at the interface of chemistry and biology. ICBS provides an important international forum that brings together cross-disciplinary scientists from academia, nonprofit organizations, government, and industry to communicate new research and help translate the power of chemical biology to advance human health.
After exciting annual meetings in Boston (USA), Kyoto (Japan), San Francisco (USA), Berlin (Germany), and Madison (WI, USA), in October 17-20, 2017, the 6th Official Conference of the ICBS will be held. During this meeting, new discoveries and insights will be shared to address emerging global challenges, foster collaborations across disciplines and across the globe, discuss ways to enhance the impact of chemical biology, and support the career development of students and young chemical biologists.
ABOUT FUTURE MEDICINAL CHEMISTRY
Future Medicinal Chemistry provides a regular platform (24 issues annually) for research in the ever-expanding and diversifying pharmaceutical chemistry community, by showcasing milestones in R&D and featuring expert analysis of emerging developments. The journal translates this through a range of article types including original research, reviews, commentaries and editorials, amongst others. The journal consistently provides high-quality and high-impact articles as demonstrated by the current impact factor of 3.556 (2016). The journal’s main focus is chemical drug discovery; however, content is also based around: computational approaches to compound synthesis, drug targeting and delivery, and novel technologies that aid in these fields. A more detailed explanation of the journal’s aims and scope can be found at: https://www.future-science.com/journals/fmc/aims. Future Medicinal Chemistry is currently supported by an international Editorial Board headed by Professor Iwao Ojima (State University of New York at Stony Brook, USA) and Professor Jonathan Baell (Monash University, Australia). The advisory board represents both academic and pharmaceutical professionals. To see a full list of associate editors and advisory board members please visit: https://www.future-science.com/journals/fmc/editors.
MedChemNet is a free communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships